We compared the effect of the PERK kinase inhibitor GSK2606414 (Axten et al., 2012) on new protein synthesis in neurons expressing (i) wild-type FUS, (ii) wild-type FUS plus thapsigargin (a well-established activator of the UPR), and (iii) ALS/FTD mutant FUS: FUS(R522G), FUS(R524S), FUS501, or FUS(R495X). Here, FUS is linked to amyotrophic lateral sclerosis.